The FDA would require medtech companies seeking certain premarket approvals to submit timely postmarket study data or risk losing those approvals.
The requirement is part of a final guidance the agency released last week, detailing how it will consider uncertainty in making benefit-risk determinations on breakthrough device PMAs, de novo classifications and humanitarian device exemptions (HDEs).
Get the full story on our sister site, Medical Design & Outsourcing.